BioSpace News Archive

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE’s existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.

Spago Nanomedical AB announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer.

Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors.

CSL Vifor and Travere Therapeutics, Inc., announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day.

Affimed N.V. announced that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager, in combination with atezolizumab, Roche’s checkpoint inhibitor, in patients with EGFR-wildtype non-small cell lung cancer has been accepted for poster presentation at 2024 American Society of Clinical Oncology Annual Meeting.

The Industrial Technology Research Institute triumphed at the recent Edison Awards™ in Fort Myers, Florida, securing recognition for four exceptional technological breakthroughs: the Novel Dual-Targeted Therapy for Glaucoma, Key Functional Cell Identity, PureTex Sustainable Decolorization Solution, and the High Resolution Full-Color Micro LED Display.

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the availability of Over the Counter (“OTC”) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”).

Parse Biosciences today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse’s Evercode™ single cell products.

Ascendis Pharma A/S announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency has granted marketing authorization for YORVIPATH® in Great Britain as a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, and has also granted YORVIPATH orphan drug status.

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of the detailed results from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR).